List of Excipients in Branded Drug ORAVERSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Septodont Inc	ORAVERSE	phentolamine mesylate	0362-0101	ACETIC ACID
Septodont Inc	ORAVERSE	phentolamine mesylate	0362-0101	EDETATE DISODIUM
Septodont Inc	ORAVERSE	phentolamine mesylate	0362-0101	MANNITOL
Septodont Inc	ORAVERSE	phentolamine mesylate	0362-0101	NITROGEN
Septodont Inc	ORAVERSE	phentolamine mesylate	0362-0101	SODIUM ACETATE

OraVerse Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

OraVerse is a sterile, preservative-free phentolamine mesylate injection used to reverse soft-tissue anesthesia and associated functional deficits after dental local anesthetic administration. Its current formulation is deliberately simple: phentolamine mesylate in an aqueous solution containing sodium chloride, hydrochloric acid for pH adjustment, and water for injection. The main commercial opportunity is not a broad excipient substitution program. It is a differentiated delivery and packaging strategy that preserves rapid onset, cartridge compatibility, sterility, and dental-office workflow while reducing manufacturing and regulatory risk.

What is OraVerse and how is it formulated?

OraVerse contains phentolamine mesylate, an alpha-adrenergic antagonist. The product is supplied as a sterile injectable dental cartridge in two strengths:

Product	Labeled strength	Approximate concentration
OraVerse	0.4 mg/0.8 mL	0.5 mg/mL
OraVerse	0.8 mg/1.7 mL	Approximately 0.47 mg/mL

The labeled inactive ingredients are sodium chloride, hydrochloric acid, and water for injection. The formulation does not rely on a preservative, surfactant, cosolvent, antioxidant, or complex carbohydrate excipient. The product is administered by intraoral submucosal injection after dental local anesthesia. [1]

The formulation objectives are straightforward:

• Maintain phentolamine solubility and chemical stability.
• Provide an isotonic or near-isotonic injection suitable for oral soft tissue.
• Avoid preservatives that may create local tolerability or compatibility concerns.
• Support sterile filling into dental cartridges.
• Permit use with standard dental syringes and needles.
• Deliver a low-volume dose with predictable handling in dental offices.

The simplicity of the formulation limits the value of conventional “new excipient” differentiation. The higher-value opportunities are in excipient optimization linked to container closure, stability, injection performance, and product presentation.

What excipients are used in OraVerse?

The current formulation uses three functional excipient components:

Excipient	Primary function	Commercial and technical relevance
Sodium chloride	Tonicity adjustment	Supports tolerability and limits the need for more complex buffering systems
Hydrochloric acid	pH adjustment	Enables pH control without adding a multicomponent buffer system
Water for injection	Vehicle	Provides a standard parenteral solvent

The absence of a conventional buffer is commercially relevant. A phosphate, citrate, acetate, or histidine buffer could alter pH stability, interaction with the cartridge system, osmolality, and local tissue tolerability. Any change would require comparative development work rather than a simple manufacturing substitution.

The product’s preservative-free status also has strategic value. Multidose preservative systems are poorly aligned with single-use dental cartridges. Benzyl alcohol, phenol, parabens, and similar preservatives could create unnecessary regulatory and clinical questions without solving a clear commercial problem.

How should an excipient strategy for OraVerse be designed?

A commercially viable strategy should prioritize formulation robustness over excipient novelty.

1. Preserve the low-complexity aqueous platform

The first-line strategy is to retain the water, sodium chloride, and pH-adjustment architecture while optimizing operating ranges for:

• pH;
• osmolality;
• extractables and leachables;
• visible and subvisible particles;
• container interaction;
• terminal or aseptic sterilization compatibility;
• long-term and accelerated stability.

A simple formulation has fewer raw materials, fewer supplier dependencies, and fewer failure modes. It also supports easier scale-up and more predictable regulatory comparability.

2. Use buffer substitution only if stability data justify it

A buffer may be commercially attractive if it improves pH control during storage or reduces degradation in a new container system. The candidate systems could include phosphate, citrate, acetate, or histidine, but each introduces tradeoffs.

Potential change	Possible benefit	Principal risk
Phosphate buffer	Strong pH control	Precipitation, compatibility, and osmolality concerns
Citrate buffer	Broad formulation experience	Local tolerability and chelation effects
Acetate buffer	Useful at mildly acidic pH	Odor, pH drift, and tissue tolerability assessment
Histidine buffer	Biopharmaceutical formulation precedent	Higher cost and limited justification for a simple small-molecule injection
Increased sodium chloride	Straightforward tonicity control	Higher osmolality and local irritation risk
Polyol such as mannitol	Tonicity and stabilization option	Added particulate, crystallization, and process-development burden

For OraVerse, a buffer change should be treated as a risk-management tool, not a marketing feature. The development case would need to show meaningful gains in shelf life, cartridge compatibility, manufacturing yield, or transport stability.

3. Optimize the container closure system

The largest excipient-adjacent opportunity may sit outside the liquid formulation. Dental cartridges use elastomeric components, glass, seals, and packaging materials that can affect product quality.

Development priorities include:

• low-extractables elastomer selection;
• reduced adsorption to cartridge and stopper materials;
• tighter control of tungsten, silicone oil, and particulate sources;
• improved resistance to breakage and leakage;
• compatibility with automated dental cartridge filling;
• validated moisture and oxygen barrier performance;
• improved dose delivery through standard dental syringes.

This approach may create meaningful product differentiation without introducing a novel chemical excipient.

What formulation patents could protect an OraVerse follow-on?

A formulation patent for a phentolamine dental product would generally need to claim more than the active ingredient in water. Potentially defensible claim categories include:

• defined pH and osmolality ranges;
• a specific phentolamine-to-buffer ratio;
• a low-degradation formulation;
• a cartridge-compatible composition;
• a particular elastomer and glass combination;
• reduced impurity formation during storage;
• a defined sterilization process;
• a ready-to-use dental delivery system;
• a combination package containing local anesthetic and phentolamine products.

The commercial strength of such claims depends on whether the formulation solves a measurable problem. A narrow composition claim with no demonstrated stability or performance advantage would have limited blocking value. A claim tied to a specific impurity profile, long-term shelf life, cartridge material, or manufacturing process could be more valuable.

Patent protection for an excipient strategy would usually be separate from protection for the active ingredient or method of use. A formulation patent would not automatically prevent a competitor from selling phentolamine in a materially different composition.

What patent term and Orange Book issues matter?

OraVerse was approved under FDA NDA 022159 in 2008. [2] A follow-on sponsor would need to assess current Orange Book listings, any remaining patents, pediatric exclusivity, and the legal status of each listed patent before selecting an ANDA or 505(b)(2) pathway. FDA Orange Book listings should be checked against the current edition because patent listings and certifications can change over time. [3]

A reformulated phentolamine product with a distinct excipient system may be better suited to a 505(b)(2) application than a conventional ANDA if the sponsor relies on published data or the reference product’s safety information while introducing clinically relevant formulation differences. An ANDA strategy would require the proposed product to meet applicable sameness and equivalence requirements.

What regulatory strategy applies to an OraVerse excipient change?

The regulatory burden depends on the scale of the change.

Change type	Likely regulatory issue
Supplier change for sodium chloride or water for injection	CMC comparability, specifications, and impurity controls
Minor pH adjustment	Stability, local tolerability, and product-quality comparability
New buffer	Expanded CMC package and possible clinical bridging
New preservative	Local safety, exposure, and preservative-effectiveness considerations
New cartridge material	Extractables, leachables, container closure, dose delivery, and stability
New delivery device	Human factors, dose accuracy, compatibility, and device regulatory requirements
New concentration or volume	Potential dosing and clinical-bridging requirements
Combination with local anesthetic	New drug-product and clinical-development complexity

Because OraVerse is injected into oral soft tissue, local tolerability is a central development endpoint. A formulation with lower systemic exposure but greater injection-site irritation would not necessarily be commercially superior.

FDA’s inactive-ingredient framework also matters. A previously used excipient may offer a lower regulatory burden than a novel excipient, but route, dose, duration, and tissue exposure remain relevant. [4]

What commercial opportunities exist for OraVerse excipient innovation?

Preservative-free premium presentation

The strongest near-term opportunity is a high-reliability, preservative-free cartridge with improved stability and packaging. Dental practitioners value products that fit standard workflows. A product that requires no mixing, refrigeration, or special device can support premium positioning if it reduces chair time or handling errors.

Improved cartridge stability

A cartridge system with better resistance to breakage, leakage, stopper coring, and particulate generation could support institutional and group-practice sales. Packaging improvements may also reduce product loss during shipping and inventory handling.

Extended shelf life

A longer shelf life could reduce dental-office waste and improve distributor economics. The value would be highest if achieved through packaging and process control rather than a complex excipient system. Stability claims must be supported by validated long-term data under the proposed storage conditions.

Alternative delivery formats

Potential formats include:

• prefilled dental syringes;
• unit-dose syringes;
• low-dead-volume cartridges;
• dose-marked delivery systems;
• kits paired with standard local anesthetic procedures.

Each format would create device, usability, sterility, and dose-accuracy requirements. The most practical opportunity is a compatible cartridge or prefilled system that does not require dentists to change injection technique.

Pediatric and orthodontic positioning

Children and orthodontic patients may represent commercially important use settings because soft-tissue numbness can interfere with eating, speaking, and accidental-bite avoidance. A smaller-volume or lower-dose presentation could improve dosing flexibility. It would require appropriate clinical support and must not be positioned solely on the basis of excipient changes.

Geographic expansion

A formulation platform designed for international markets should account for:

• different dental cartridge standards;
• local preservative expectations;
• pharmacopoeial requirements;
• container-closure availability;
• cold-chain and transport conditions;
• country-specific registration pathways.

A low-excipient formulation can simplify supply qualification across regions, but cartridge dimensions and packaging systems may require local adaptations.

How does OraVerse compare with competing approaches?

OraVerse has a distinct mechanism and use case rather than a direct formulation competitor. The main alternatives are waiting for local anesthetic effects to resolve, using different dental anesthesia protocols, or developing other reversal agents.

Commercial factor	OraVerse	Reformulated phentolamine product	Non-phentolamine alternative
Formulation complexity	Low	Low to moderate	Unknown and product-specific
Excipient differentiation	Limited in current composition	Moderate through stability and delivery	Potentially higher
Regulatory pathway	Existing NDA reference	505(b)(2) or other applicable route	New development burden
Workflow advantage	Dental cartridge administration	Could improve convenience	Must establish new workflow
Patent opportunity	Formulation, packaging, process	More opportunities if performance improves	Depends on active and delivery system
Commercial risk	Established clinical concept	Bridging and adoption risk	Higher clinical and regulatory risk

The best follow-on strategy is likely an incremental product with superior handling, stability, or packaging rather than an entirely new excipient platform.

Which companies could challenge or license an OraVerse opportunity?

Potential participants include:

• dental pharmaceutical companies;
• generic injectable manufacturers;
• contract development and manufacturing organizations;
• dental cartridge and primary-packaging suppliers;
• specialty pharmaceutical companies focused on office-based procedures;
• companies developing local-anesthetic delivery systems.

Licensing value would increase if the sponsor owns a formulation patent, a validated cartridge platform, or an FDA-ready CMC package. A generic manufacturer may prefer a narrow formulation improvement that supports a 505(b)(2) application. A dental company may value workflow integration and distribution more than composition claims.

Publicly reported standalone revenue for OraVerse is not generally disclosed. Revenue exposure should therefore be modeled using dental procedure volume, adoption rate, net price, geographic penetration, and competitor entry timing rather than relying on product-level historical sales.

What generic entry risks exist for OraVerse?

Generic and follow-on entry could occur through several paths:

1. A conventional ANDA for a composition and presentation that meets applicable requirements.
2. A 505(b)(2) product with a different excipient system, concentration, device, or presentation.
3. A competing phentolamine product with a different dental delivery system.
4. A compounded or office-use alternative, subject to applicable federal and state requirements.

The principal barriers are sterile manufacturing, dental cartridge filling, product-quality consistency, clinical bridging, and distribution into dental practices. The active ingredient itself is unlikely to be the only barrier. Manufacturing know-how and primary packaging may be more important than excipient complexity.

Key Takeaways

• OraVerse uses a simple preservative-free aqueous formulation based on sodium chloride, hydrochloric acid, and water for injection.
• The highest-value excipient strategy is formulation robustness, not novelty.
• Cartridge materials, elastomer selection, particulate control, and dose-delivery reliability are major commercial opportunities.
• Buffer substitution should be pursued only when it produces measurable stability or manufacturing gains.
• A reformulated phentolamine product may fit a 505(b)(2) strategy, depending on the final composition and reliance on the reference product.
• Formulation, container-closure, manufacturing, and delivery-system patents are more promising than broad claims to phentolamine in an aqueous vehicle.
• The strongest commercial product would preserve preservative-free, single-use operation while improving shelf life, handling, packaging, or dose flexibility.
• Generic entry risk is driven by sterile manufacturing and dental-cartridge capabilities as much as by patent protection.

FAQs

Can OraVerse use a different preservative?

A different preservative is technically possible, but it would add local tolerability, preservative-effectiveness, exposure, and regulatory requirements. A preservative-free product remains the lower-risk commercial position.

Is a buffer necessary for a phentolamine dental injection?

Not necessarily. OraVerse uses hydrochloric acid for pH adjustment rather than a conventional multicomponent buffer. A buffer would need to demonstrate a clear stability or manufacturing benefit.

Could a new OraVerse formulation qualify as an ANDA?

Possibly, if it satisfies applicable sameness and equivalence requirements. A meaningful change in excipients, concentration, delivery system, or clinical use may make a 505(b)(2) pathway more appropriate.

What is the most defensible patent claim for a follow-on product?

Claims covering a defined stability profile, impurity limit, cartridge system, manufacturing process, or delivery configuration are generally more defensible than claims covering only a simple aqueous phentolamine composition.

What is the best commercial differentiation for a generic OraVerse product?

The most practical differentiation is a reliable preservative-free cartridge or prefilled system with improved shelf life, reduced breakage and particulate risk, easy dose selection, and compatibility with existing dental workflows.

References

1. U.S. Food and Drug Administration. (n.d.). OraVerse (phentolamine mesylate) injection, prescribing information.
2. U.S. Food and Drug Administration. (2008). OraVerse approval letter and NDA 022159 materials.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2019). Inactive ingredient database.